SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
ARRIS - Another partner
An SI Board Since June 1996
Posts SubjectMarks Bans Symbol
353 2 0 AXPH
Emcee:  Paul Getman Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
278 AH: >>My guess is that all this may indicate a bottom for the biotechs. David Bogdanoff-12/3/1997
277 Miljenko, you probably saw this already, but for the benefit of anyone who has Pseudo Biologist-12/3/1997
276 >>I have noticed that positive news seems to be built into the price of Andrew H-12/3/1997
275 John; Could you or someone else put Delta and this patent into terms that an avSteve Lokness-12/3/1997
274 David: I am bonded by on-line subscription and can't post full articles. NMiljenko Zuanic-12/2/1997
273 MZ; >>I wish they would just admit defeat with APC-366 and move on.<&David Bogdanoff-12/2/1997
272 David: >>I wish they would just admit defeat with APC-366 and move on.&lMiljenko Zuanic-12/2/1997
271 Hi John: Thanks for your view of the Delta PI. Ended we all lost few nerves waMiljenko Zuanic-12/2/1997
270 JD: >>I wish they would just admit defeat with APC-366 and move on.<&lDavid Bogdanoff-12/2/1997
269 Chiron Grants Bristol-Myers Squibb and Arris First Non-Exclusive HCV Licences Douglas Nordgren-12/2/1997
268 Well, the cat's out of the bag... This is a good idea but they are still vJohn Dwyer-12/2/1997
267 MJ and all; WSJ 12/2/97 Arris Pharma Gets Patent For Protease Inhibition TeTomOrt-12/2/1997
266 ....and you discovered *hot water*, the biggest discovery after Newton stoped sMiljenko Zuanic-12/2/1997
265 Agouron has been working on this much longer and is at least 2-3 yrs closer to JOHN W.-12/2/1997
264 I should preface this by pointing out that I am not implying this partnership iJames Silverman-12/1/1997
263 AH: Agree hard to believe. Goes to show market inefficiencies exist big time. David Bogdanoff-12/1/1997
262 Important new partnership announcement today barely budged the stock off its 2 Andrew H-12/1/1997
261 Arris bought Sequana to give them a platform technology in disease gene identifbiopicker-11/24/1997
260 Biopicker, Very nice summary. I agree with most of what you said and feel thaJohn Dwyer-11/24/1997
259 Biopicker; Do you have any knowledge of Dr. Welton? Is getting her to join up wSteve Lokness-11/23/1997
258 In response to your question, what I meant by maximizing shareholder value is tbiopicker-11/23/1997
257 Thanks biopicker for a most excellent and articulate analysis of Axys. I agreAndrew H-11/23/1997
256 As an aside, on Thursday, after the close, Arris announced that Ann F. Welton,biopicker-11/23/1997
255 Very nice presentation. An investor in development-stage biotechs could not helCYBERKEN-11/23/1997
254 In my opinion, the combined entity of Sequana and Arris, which will be named Axbiopicker-11/23/1997
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News